% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Grassl:284811,
      author       = {N. Grassl$^*$ and K. Sahm$^*$ and H. Süße and I.
                      Poschke$^*$ and L. Bunse$^*$ and T. Bunse$^*$ and T.
                      Boschert$^*$ and I. Mildenberger$^*$ and A.-K. Rupp and M.
                      P. Ewinger and L.-M. Lanz and M. Denk$^*$ and G. Tabatabai
                      and M. W. Ronellenfitsch and U. Herrlinger and M. Glas and
                      D. Krex and P. Vajkoczy and A. Wick and I. Harting and F.
                      Sahm$^*$ and A. von Deimling$^*$ and M. Bendszus and W. Wick
                      and M. Platten$^*$},
      title        = {{INTERCEPT} {H}3: a multicenter phase {I} peptide vaccine
                      trial for the treatment of {H}3-mutated diffuse midline
                      gliomas.},
      journal      = {Neurological research and practice},
      volume       = {5},
      number       = {1},
      issn         = {2524-3489},
      address      = {[London]},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2023-02110},
      pages        = {55},
      year         = {2023},
      note         = {#EA:D170#LA:D170# / HI-TRON},
      abstract     = {Diffuse midline gliomas (DMG) are universally lethal
                      central nervous system tumors that carry almost unanimously
                      the clonal driver mutation histone-3 K27M (H3K27M). The
                      single amino acid substitution of lysine to methionine
                      harbors a neoantigen that is presented in tumor tissue. The
                      long peptide vaccine H3K27M-vac targeting this major
                      histocompatibility complex class II (MHC class
                      II)-restricted neoantigen induces mutation-specific immune
                      responses that suppress the growth of H3K27M+ flank tumors
                      in an MHC-humanized rodent model.INTERCEPT H3 is a
                      non-controlled open label, single arm, multicenter national
                      phase 1 trial to assess safety, tolerability and
                      immunogenicity of H3K27M-vac in combination with standard
                      radiotherapy and the immune checkpoint inhibitor
                      atezolizumab (ATE). 15 adult patients with newly diagnosed
                      K27M-mutant histone-3.1 (H3.1K27M) or histone-3.3 (H3.3K27M)
                      DMG will be enrolled in this trial. The 27mer peptide
                      vaccine H3K27M-vac will be administered concomitantly to
                      standard radiotherapy (RT) followed by combinatorial
                      treatment with the programmed death-ligand 1 (PD-L1)
                      targeting antibody ATE. The first three vaccines will be
                      administered bi-weekly (q2w) followed by a dose at the
                      beginning of recovery after RT and six-weekly
                      administrations of doses 5 to 11 thereafter. In a safety
                      lead-in, the first three patients (pts. 1-3) will be
                      enrolled sequentially.H3K27M-vac is a neoepitope targeting
                      long peptide vaccine derived from the clonal driver mutation
                      H3K27M in DMG. The INTERCEPT H3 trial aims at demonstrating
                      (1) safety and (2) immunogenicity of repeated fixed dose
                      vaccinations of H3K27M-vac administered with RT and ATE in
                      adult patients with newly diagnosed H3K27M-mutant
                      DMG.NCT04808245.},
      keywords     = {Antigen (Other) / Atezolizumab (Other) / Central nervous
                      system tumor (Other) / Diffuse midline glioma (Other) /
                      Glioma (Other) / Immunotherapy (Other) / T cell (Other) /
                      Vaccine (Other)},
      cin          = {D170 / HD01 / TU01 / B300},
      ddc          = {610},
      cid          = {I:(DE-He78)D170-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)TU01-20160331 / I:(DE-He78)B300-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37853454},
      doi          = {10.1186/s42466-023-00282-4},
      url          = {https://inrepo02.dkfz.de/record/284811},
}